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Epstein-Barr Virus-Associated Syndromes in 
Immunosuppressed Liver Transplant Recipients 
Clinical Profile and Recognition on Routine 
Allograft Biopsy 
P.S. Randhawa, M.B.B.S., M.D., R.S. Markin, M.D., Ph.D., 
T.E. Starzl, M.D., Ph.D., and A.J. Demetris, M.D. 
The clinical profIle and histopathologic changes in needle 
biopsies of the liver were studied in 10 cases of acute 
Epstein-Barr virus infection occurring in liver transplant 
recipients. The systemic viral syndrome in four cases re-
sembled that seen in infectious mononucleosis, whereas 
in six others it was characterized by atypical signs and 
symptoms in the form of jaw pain, arthralgias, joint space 
effusions, diarrhea, encephalitis, pneumonitis, mediasti-
nallymphodenopathy, and ascites. Laboratory investiga-
tion showed marked elevations in hepatocellular enzymes 
and circulating atypical lymphocytes in the peripheral 
blood. Pancytopenia was noted in eight cases. A range of 
histopathologic changes was noted in the allografts rang-
ing from alterations typically observed in infectious 
mononucleosis to a distinctive constellation character-
ized by (a) mixed mononuclear portal and sinusoidal in-
filtrates containing atypical large noncleaved cells and im-
munoblasts; (b) associated lobular activity indicative of a 
hepatitic process, and (c) relatively mild duct damage not 
in proportion to the severity of the inflammatory infil-
trates. The patients responded to reduced immunosup-
pression, but recurrent viral syndromes occurred in four 
instances and one patient died of systemic lymphoprolif-
erative disease. 
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Epstein-Barr Virus (EBV) infections are com-
monly observed in patients after orthotopic liver 
transplantation and serologic evidence of active dis-
ease is demonstrable in 24% of cases (15). Most 
often this represents asymptomatic infection, but 
1-2% of transplant recipients develop persistent or 
recurrent disease culminating in the development of 
posttransplant lymphoproliferative disorders, some 
of which behave like aggressive lymphomas (9). 
Early recognition of EBV infection and treatment 
with reduced immunosuppression and acyclovir has 
the potential of preventing such complications. For 
this reason we undertook a retrospective analysis to 
define the clinical presentation, liver function tests, 
hematological profile, histopathologic changes in 
liver allograft, and final outcome in 10 cases with 
EBV syndrome occurring after liver replacement in 
patients maintained on cyclosporine-prednisone im-
munosuppression. 
It is shown that the observed clinical profile over-
laps the syndrome commonly seen in infectious 
mononucleosis, but, often is different enough that it 
may go clinically unrecognized. The constellation 
of changes seen in needle biopsies of the allograft in 
these cases is sufficiently distinctive for the pathol-
ogist to suggest the diagnosis of EBV infection on 
histopathological grounds alone. 
MATERIALS AND METHODS 
The cases described in this series were selected 
by reviewing the clinical and serologic data on adult 
orthotopic liver transplant recipients who had liver 
biopsies submitted to the Department of Pathology, 
Presbyterian University Hospital, Pittsburgh, from 
1985 to 1988. 
The 10 cases selected for this study fulfilled the 
following criteria. 
Case Age (yr)1 
no. sex 
53/M 
2 221M 
3 44/F 
4 28/F 
5 201M 
6 58/M 
7 26/F 
8 18/F 
9 54/M 
10 42/F 
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TABLE 1. Clinical features of Epstein-Barr virus (EBV) Syndrome in orthotopic liver 
transplant recipients 
Period of 
onset of 
EBV 
syndrome 
following Presenting Outcome of 
Primary transplant clinical initial EBV Recurrent 
disease (days) features syndrome EBV syndromes 
CC 63 Fever, pharyngitis, Resolution over 5 wk PTLD lung and ileum 
cervical and axillary resolved over 8 wk 
LN 
PSC 43 Fever, pharyngitis Resolution over 8 wk NIL 
generalized LN, Sp, 
icterus 
CC 14 Fever, generalized LN, Resolution over 8 wk NIL 
icterus 
CC 27 Arthralgia right knee, Resolution over 2 wk Systemic PTLD, fatal 
petechial rash over 1 mo 
CC 603 Fever, pharyngitis, Developed systemic 
paratracheal LN, PTLD, death at 8 wk 
diarrhea, jaw pains, 
arth ralgias, right 
pleural effusion, Sp 
Alcoholic 31 Fever, cervical and Resolution over 2 wk Meningoencephalitis 
cirrhosis axillary LN resolving over 5 days 
a-1ATD 74 Icterus, axillary LN Resolution over 3 wk SystemiC PTLD 
responsive to 
immunomodulation 
Wilson's 10 Fever, sinus headaches Resolution over 3 wk NIL 
generalized LN 
CAH-B hepatoma 36 Fever, generalized LN Developed systemic Not applicable 
PTLD, fatal over 2 wk 
CAH cirrhosis 623 Fever, pharyngitis, Resolved over 11 wk NIL 
generalized LN, Sp, 
ascites, dysarthria, 
dysmetria, 
pneumonitis 
539 
Final 
outcome of 
EBV 
infection 
Resolution 
Resolution 
Resolution 
Death 
Death 
Resolution 
Resolution 
Resolution 
Death 
Resolution 
CC, cryptogenic cirrhosis; PSC, primary sclerosing cholangitis; CAH, chronic active hepatitis; a-1ATD, a-1 antitrypsin deficiency; LN, lymphad-
enitis; Sp, splenomegaly; PTLD, posttransplant Iymphoproliferative disorders. 
TABLE 2. Occurrence of infectious and allograft rejection episodes in relation to onset of 
EBV syndrome 
Timing of episodes of allograft rejection" 
Case Before diagnosis 
no. of EBV (days) 
None 
2 -35, -13 
3 None 
4 -10 
5 None 
6 -20 
7 -33 
8 -2 
9 -3, -37 
10 None 
After diagnosis 
of EBV (days) 
+17 
+18 
+5, +38, +111 
+133, +169, +307 
None 
+ 11, +80 
+8 
+13 
None 
+25 
Infectious episodes 
Before diagnosis 
of EBV 
Blood cultured staphylococci and 
CMV 
None 
Herpes simplex (lip) 
CMV viremia 
CMV hepatitis, pneumocytis infection 
Herpes simplex, Streptococcus 
viridans pharyngitis 
CMV uveitis 
Urine-cultured Candida stellatoidea 
None 
None 
After diagnosis 
of EBV 
Candida pharyngitis, CMV 
pneumonitis, staphylococcal 
septicemia 
Escherichia coli (abdominal wound) 
None 
Urine-cultured CMV, E coli, and S 
fecalis 
S viridans pharyngitis 
Cholangitis, bile-cultured coagulase 
negative staphylococci, S feca/is 
Bile-cultured citrobacter, S fecium, 
candida 
Groin wound infection by S fecalis, 
coagUlase-negative staphylococci 
None 
Urine cultured E coli, enterococci, 
candida. Bronchoalveolar 
lavage-cultured candida 
a _, number of days rejection preceded the onset of a clinical syndrome; +, number of days that rejection occurred after the 
diagnosis of viral syndrome. 
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TABLE 3. Peak values of abnormalities in liver function tests concurrently with the clinical 
viral syndrome 
Case 
Bilirubin (mg/dl) 
no. Total Direct % Direct 
1 2.0 0.4 16.6 
2 5.6 4.7 85.9 
3 7.6 5.3 69.7 
4 5.0 3.2 64.0 
5 0.7 NA NA 
6 1.7 1.2 70.6 
7 10.2 8.8 86.3 
8 2.6 1.7 65.3 
9 11.7 8.8 75.2 
10 0.7 NA NA 
NA, not available. 
1. There was clinical and serologic evidence of 
recent EBV infection in the form of fever, sore 
throat, lymphadenitis, icterus, or splenomegaly ac-
companied by either a positive anti-viral capsid an-
tigen (VCA) IgM or a recent fourfold rise in titers of 
anti-VCA IgG antibodies. Cases known to be sero-
negative before transplantation were considered 
primary EBV infection, whereas all other cases 
were considered to be a reactivation of a latent in-
fection. 
2. Needle biopsies of liver concurrent with the 
clinical EBV syndrome were available. 
3. Absence of evidence for other known caus-
ative agents of mononucleosis-like syndromes such 
as active cytomegaloviral, hepatitis B, or herpes 
simplex infections, and drug reactions. 
The medical records of these patients were re-
viewed for clinical presentation, liver function 
tests, hematologic profile, occurrence of infectious 
and allograft rejection episodes, and response to re-
duced immunosuppression and acyclovir adminis-
tration. Serologic titers of anti-EBV antibodies per-
formed by standard immunofluorescence tech-
SGOT SGPT Alkaline 'Y Glutamyl (lUlL) (lUlL) phosphatase transferase 
128 273 789 243 
66 80 1,056 572 
862 518 1,198 1,032 
45 57 255 356 
73 17 109 47 
102 99 741 341 
107 160 988 1,438 
124 335 475 446 
3,233 1,043 701 201 
306 281 441 278 
niques were recorded as available in the files. 
Histopathological changes in the liver biopsies were 
evaluated by examination of 5-flm paraffin-
embedded sections stained with hematoxylin eosin, 
periodic acid-Schiff, and trichrome techniques. 
RESULTS 
Clinical Presentation 
There were five men and five women ranging in 
age from 18 to 58 years (mean 37, median 35; Table 
1). The primary liver diseases for which liver trans-
plantation was performed in these patients were 
cryptogenic cirrhosis (four cases), primary scleros-
ing cholangitis, chronic active (clinically non-A 
non-B) hepatitis with cirrhosis, hepatitis B cirrhosis 
associated with hepatocellular carcinoma, alcoholic 
cirrhosis, alpha-I-antitrypsin deficiency, and Wil-
son's disease (one case each). Cyclosporine was ad-
ministered in the dose of 2 mg/kg/day in i. v. on day 
of surgery followed by 6 mg/kg/day orally. Pred-
nisone was administered in a dose of 200 mg/day 
TABLE 4. Hematological parameters in patients with EBV syndromes on 
cyclosporin-prednisone immunosuppression following liver transplantation 
Total leukocytic 
countl1,OOO mm3 Lymphocytes (%) Hemoglobin Hemoglobin Lowest Peak PTa Peak pna 
Case (% atypical trough" peak" platelet (control (Control 
no. Trough" Peak" forms) (g/dl) (g/dl) countl1,OOO mm3 11.8 seconds) 25.0 seconds) 
1 3.1 6.9 84 (20) 9.7 10.4 45 13.5 31.4 
2 2.4 5.0 57 (7) 8.1 11.9 113 14.3 39.5 
3 7.5 16.5 39 (19) 8.9 12.0 110 14.5 31.9 
4 3.1 6.7 43 (29) 7.8 10.2 73 16.1 33.8 
5 2.3 6.4 84 (42) 5.7 11.1 11 18.3 33.3 
6 5.8 17.4 68 (55) 9.3 10.9 99 13.5 34.1 
7 3.6 30.1 62 (12) 6.7 12.7 378 13.7 34.4 
8 3.0 9.3 38 (11) 7.5 10.2 43 14.1 31.8 
9 3.9 11.0 44 (16) 9.3 12.5 41 22.1 71.4 
10 1.2 3.8 65 (6) 8.8 10.8 92 13.3 32.7 
PT, prothrombin time; PTI, partial thromboplastin time. 
Peak and trough refers to the high and low values obtained during the course of the viral syndrome. 
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TABLE 5. Serological profile of EBV infections occurring in immunosuppressed liver 
transplant recipients 
Pretransplant 
Posttransplant serology 
Type of 
Case no. serology Anti -VCA Anti-EA Anti-EBNA infection 
1 -VE 1 :10 1 :10 -VE Primary 
2 -VE 1 :20 -VE - VE Primary 
3 Ant i-VCA IgG 1 :40, anti-EA 1: 1 0 1 :640 1 :20 1 :20 Reactivation 
4 -VE 1 :80 1 :20 NA Primary 
5 NA 1 :640 - VE -VE Indeterminate 
6 ANTI·VCA 1 :320, ANTI-EA 1:5 1 :1280 1 :20 NA Reactivation 
7 -VE 1 :640 1 :80 - VE Primary 
8 Anti-VCA IgG 1 :50, anti-VCA IgM-VE, anti-EBNA 1:8 1 :50 IgG 1 :20 1 :2 Reactivation 
1 :10 IgM NA 
9 Anti-VCA 1 :20, anti-EA 1 :10 1 :80 1 :20 NA Reactivation 
10 -VE 1 :320 1 :80 NA Primary 
VCA, viral capsid antigen ; EA, early antigen ; EBNA, Epstein-Barr nuclear antigen ; - VE , negative antibody profile; NA, not 
available. 
i. v. on the day of surgery followed by tapering to an 
oral maintenance dose of 20 mg/day. 
Viral syndromes were clinically recognized 10-
623 days following transplantation (mean 219 , me-
dian 39). Fever (n = 8)' pharyngitis (n = 4), and 
lymphadenopathy (n = 9) were the most common 
FIG. 1. Portal tract infiltrate comprising small and 
large atypical lymphocytes with differentiation to im-
munoblasts and mature plasma cells. The normal por-
tal tract landmarks are obscured. 
manifestations. Lymph node enlargement was typ-
ically most noticeable in the cervical and axillary 
regions (n = 4) but was also frequently generalized 
(n = 5). The spleen was palpable in four cases. 
Hepatomegaly was not described but icterus was 
noted in three cases. Atypical symptoms in the form 
of jaw pain , arthralgias, joint space effusions, diar-
FIG. 2. Atypical mononuclear cells in the portal tract 
(see also inset) are seen to spill over into the hepatic 
lobule associated with hepatocyte necrosis. 
Am J Surg Palhol, Vol. 14. No.6. 1990 
542 P.S. RANDHA WA ET AL. 
rhea, skin rash, encephalitis, pneumonitis, medias-
tinallymph node enlargement, ascites, and ileal per-
foration were observed in six instances either at 
initial presentation or on subsequent follow-up. 
Multiple other infections and rejection episodes 
were documented in these patients before and after 
the diagnosis of EBV infection (Table 2). 
Liver Function Tests and Hematologic Profile 
Liver function tests (Table 3) showed elevations 
of bilirubin up to 11.7 mg%, the conjugated form 
constituting 17--86% of the total. Serum glutamic-
oxaloacetic transaminase (SGOT) and serum glu-
tamic-pyruvic transaminase (SGPT) levels were 
raised moderately and usually less than 1,000 lUlL, 
except in case 9, where massive hepatic necrosis 
was documented at autopsy. The alkaline phos-
phatase and gamma glutamyl transferase tended to 
be somewhat higher and peak values of 1,198 lUlL 
and 1,438 lUlL respectively, were recorded. Hema-
tological parameters (Table 4) typically showed a 
low hemoglobin, thrombocytopenia, and mildly de-
FIG. 3. The sinusoids show mononuclear cells ar-
ranged in a linear beadlike fashion. The surrounding 
hepatocytes show mild lobular disarray of swollen 
liver cells forming pseudorosettes. 
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ranged prothrombin time and partial thromboplastin 
time. Total leukocyte counts showed a varied pic-
ture with leukopenia seen in some patients but leu-
kocytosis in others. Differential counts showed 
lymphocytic preponderance (38-84%), and circulat-
ing atypical lymphocytes (&-55%) were always de-
monstrable. 
Serology 
Serologic studies demonstrated recent EB V in-
fection in all patients (Table 5). Comparison of pre-
and posttransplantation anti-VCA titers available in 
nine cases allowed five cases to be characterized as 
primary and four as reactivation infection. Devel-
opment of anti-early antigen (EA) antibody was 
noted in six cases, and anti-Epstein-Barr nuclear 
antigen (EBNA) , antibody in two cases. 
Histopathology 
Histopathologic examination showed prominent 
portal and periportal mononuclear infiltrates. In six 
FIG. 4. The sinusoidal infiltrates in this case are ar-
ranged in focal aggregates. Hepatocyte regenerative 
activity is seen in the form of binucleate cells and nu-
clear pleomorphism. 
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cases small and large atypical lymphocytes with dif-
ferentiation to immunoblasts and plasma cells was 
present (Fig. I). Five cases demonstrated spillover 
of the infiltrate into the lobule (Fig. 2). The lobule 
typically showed features of a "reactive" or low-
grade hepatitis in the form of hepatocellular swell-
ing, focal acidophilic necrosis, and mild lobular dis-
array. Regenerative activity was seen in the form of 
double-layered liver cords, pseudorosette forma-
tion, cytoplasmic basophilia, nuclear pleomor-
phism, and mitotic figures. The sinusoids contained 
linearly aligned (Fig. 3) and focally aggregated (Fig. 
4) mononuclear cells, similar to those seen in the 
portal tracts. In one case the infiltrate was granulo-
matoid (Fig. 5). Bile duct damage affecting 10--70% 
of the total number of ducts present was seen in 
seven cases, but the severity and prevalence of 
damage appeared not to be in proportion to that 
expected for rejection. Subendothelial localization 
of lymphocytes was seen in the portal or central 
veins in six cases and mild focal canalicular chole-
stasis occurred in four cases. The changes observed 
were not always florid or uniformly distributed 
throughout the specimens. Three cases (cases 1, 4, 
FIG. 5. III-defined granulomas located sinusoidally 
were noted in this biopsy. Gram, Grocott, and acid fast 
bacilli (AFB) stains were negative. 
FIG. 6. Illustration of a case with portal tracts contain-
ing a very sparse inflammatory infiltrate. One portal 
tract in the same biopsy, however, contained dense 
mononuclear infiltrates similar to those shown in Fig . 
1. Such focal lesions are liable to be missed in small 
specimens. 
and 5) merely showed a nonspecific reactive type 
hepatitis. The liver sinusoids showed surprisingly 
mild lymphocytosis despite a concurrent systemic 
posttransplant Iymphoproliferative disease. It was 
also noticed that the infiltration in zone 1 varied in 
severity in the same specimen, and portal triads 
with only sparse mononuclear cells (Fig. 6) could be 
recognized in biopsies with dense portal lympho-
cytic and immunoblastic infiltrates elsewhere. Se-
quential biopsies available in cases 2, 3, 6, 7, and 10 
showed histological resolution of liver cell injury 
concomitant with clinical improvement in the viral 
syndrome after a reduction in immunosuppression. 
Complete resolution of hepatitis could be docu-
mented in cases 3, 6, and 10 at 69-106 days after the 
initial biopsy. In cases I and 4, an initial clinical 
improvement was followed by the development of a 
systemic posttransplant Iymphoproliferative disor-
der. A sufficient number of biopsies were not avail-
able in cases 5, 8, and 9 for any meaningful tem-
poral clinicopathologic correlation. Another general 
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observation made on serial biopsies was an increase 
in bile duct damage, venous "endothelialitis" and a 
mixed inflammatory infiltrate in the portal tracts 
(Fig . 7). This presumably reflected enhanced cellu-
lar rejection secondary to the reduced immunosup-
pression instituted in these patients after the diag-
nosis of EBV infection . Attempts to detect the EBV 
genome within the liver tissue using a commercially 
available in situ hybridization kit was unsuccessful 
(EBV Pathogene kit , ENZO , New York). 
Treatment and Clinical Course 
Patient 4 received no specific treatment. The di-
agnosis was missed because of the atypical presen-
tation and a serologic clue to EBV infection was 
obtained only after the patient had been discharged . 
The patient presented 9 months later with recurrent 
EBV infection complicated by diffuse intraabdom-
inal PTLD and died (Figs . 8-11). The remaining 
cases were treated by a reduction of immunosup-
pression and a course of acyclovir therapy . Five 
cases had a benign self-limited course with a return 
FIG. 7. Bile duct damage and subendothelial inflam-
mation of a portal vein developed in this case after the 
suggested diagnosis of EBV hepatitis on a preceding 
biopsy. This led the clinical team to reduce the level of 
immunosuppression in this patient. 
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of clinical and hematological parameters to normal 
over a period of 2-8 weeks . Recurrent viral syn-
dromes developed in 4 cases (cases 1, 4, 6, and 7). 
Interestingly three of the recurrences (cases 1, 6, and 
7) also responded to reduced immunosuppression. 
DISCUSSION 
The predominant clinical manifestations of EBV 
infection seen in these transplant recipient patients , 
namely fever, lymphadenitis, pharyngitis , spleno-
megaly, and icterus, do not differ from those of 
classic infectious mononucleosis (1M). However, 
atypical signs and symptoms, prolonged viral syn-
dromes, and recurrent attacks were noted in several 
patients. This presumably represents modification 
of the natural course of EBV infection by an under-
lying state of immunosuppression as has been ob-
served for salmonellosis (13), cytomegalovirus (18) , 
herpes simplex, and varicella zoster (15) infections. 
Liver function tests in uncomplicated 1M have 
been studied by several authors . Serum bilirubin 
elevations have been noted in up to 21 % of cases, 
but values exceeding 6 mg% are unusual. Serum 
glutamate oxaloacetate transaminase (SGOT), se-
rum glutamate pyruvate transaminase (SGPT), or 
gamma glutamyl transferase (GGT) in excess of 500-
600 lUlL are uncommon (4), and alkaline phos-
phatase activity generally does not exceed 400 lUlL 
(5,14). Our data indicate that EBV hepatitis in im-
munosuppressed subjects may show biochemical 
hepatocellular injury of greater magnitude than is 
usually observed in immunocompetent hosts . 
The hematological profile commonly showed 
atypical lymphocytosis , thrombocytopenia , granu-
locytopenia , and anemia. Thrombocytopenia and 
granulocytopenia are common in 1M (1 ,7). Signifi-
cant bleeding and fatal agranulocytosis have been 
described occasionally (l0,17). The underlying 
mechanism may be a combination of hypersplenism 
anti platelet antibodies and bone marrow suppres-
sion . Anemia, however, is not a characteristic fea-
ture of classic 1M in contrast to the universal oc-
currence of significant anemia in the present series. 
Concurrent thrombocytopenia and neutropenia sug-
gest bone marrow depression as the principal un-
derlying factor. Hemophagocytosis as a cause of 
progressive pancytopenia in EBV infections has 
also been documented (8,12,19). 
The available serologic titers to EBV antigens 
conclusively established that five of 10 symptom-
atic cases (50%) represent individuals with no prior 
exposure to EBV. In general , because 90% of pa-
tients referred to our institution for transplantation 
are EBV seropositive (and the majority of these 
have an uneventful postoperative course), it implies 
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FIG. 8. Pan lobular necrosis ob-
served in a fatal case with EBV-
associated hepatitis. Systemic 
PTLD involviqg the lungs, gastro-
intest inal tract, lymph nodes, 
spleen, bone marrow, adrenals, 
pancreas, and testes was docu-
mented at autopsy. Inset shows 
necrotic liver tissue at a higher 
magnification (PT, portal tract; 
CV, central vein) . 
FIG. 9. Deep hilar section from the case illustrated in 
Fig . 8. The mononuclear infiltrate is seen involving a 
nerve bundle (autopsy material, case 4). 
FIG. 10. The "malignant potential" of the mononu-
clear infiltrate in fatal EBV-associated hepatitis is il-
lustrated by its extension beyond the confines of the 
liver into the hilar fat (autopsy material, case 4). 
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FIG. 11. Portal veins from the deep hilum of case 4 
studied at necropsy. The cells seen intraluminally had 
the same atypical and blastic features as those seen in 
the portal tracts in the antemortem needle biopsy. The 
systemic dissemination of these infiltrates by the vas-
cular route is perhaps one of the pathways leading to 
the development of PTLD lesions in multiple organ 
systems. 
that exposure to EBV for the first time under the 
setting of posttransplant immunosuppression car-
ries a high risk of developing atypical systemic EBV 
syndromes. 
Our experience with evaluation of needle biop-
sies of liver performed on these patients indicates 
that histopathologic changes associated with EBV 
syndrome are sufficiently distinctive in many cases 
to at least suggest this diagnosis to the treating phy-
sicians, who could then obtain serologic confirma-
tion and proceed to reduce the level of immunosup-
pression . Infectious mononucleosis can be histo-
pathologically confused with non-A, non-B 
hepatitis, and serologic correlations are advisable. 
The most distinctive cases of EBV involvement of 
the allograft are characterized by a mononuclear 
portal infiltrate comprising small lymphocytes, 
plasma cells, large cleaved/noncleaved cells, and 
immunoblasts. Granulomas may also be found (6). 
Although a mononuclear portal infiltrate occurring 
in a posttransplant liver biopsy normally points to 
the onset of allograft rejection (16), a monomor-
phous portal and sinusoidal infiltrate lacking poly-
morphs or eosinophils, containing a significant 
number of atypical large noncleaved cells, and as-
sociated with hepatitic changes should arouse the 
suspicion of a viral syndrome. These changes over-
lap with , but are distinct from, those of cellular re-
jection (3) . EBV -induced bile duct damage has been 
demonstrated in fatal cases of X-linked lymphopro-
liferative syndrome (2,8). Arteritis and venulitis 
have also been documented in EBV pneumonitis in 
immunosuppressed heart-lung transplant recipients 
(11). However, when a mixed polymorphonuclear 
eosinophilic and mononuclear inflammatory infil-
trate occurs, duct damage and vascular lesions are 
readily apparent, and allograft rejection should be 
considered the primary process. In difficult cases 
access to information such as the occurrence of fe-
brile syndromes, serology, and blood cyclosporine 
levels can aid in resolving the differential diagnosis 
between acute cellular rejection and EBV hepatitis. 
Of course these two processes may coexist or occur 
sequentially. In fact, a reduction in immunosup-
pression following a diagnosis of EBV hepatitis fre-
quently triggers allograft rejection to a variable de-
gree. 
In summary, EBV -associated hepatitis in immu-
nosuppressed patients encompasses a very wide 
Development 
/:Ca~ Death FIG. 12. Illustration of the possible outcomes of EBV infection in im-
munosuppressed liver transplant 
recipients. Orthotopic ---_a EBV syndrome Resolution 
liver transplantation 
Recurrence 
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clinicopathological spectrum. Examination of some 
biopsies reveals only a mild nonspecific hepatitis, 
whereas other specimens show dense portal and si-
nusoidal infiltrates with large atypical mononuclear 
cells. Massive panlobular necrosis can also occur, 
as has been reported in sporadic fatal infectious 
mononucleosis (2). The ultimate clinical outcome 
(Fig. 12) in most cases is a resolution in response to 
reduced immunosuppression, but there is a ten-
dency to the occurrence of recurrent viral syn-
dromes and occasional progression to posttrans-
plant lymphoproiiferative disorders. 
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Note added in proof: Attempts to demonstrate EBV 
genomes within the lesions using the EBV pathogene kit 
were unsuccessful, and exhausted the entire tissue em-
bedded in the paraffin blocks of these cases. In situ hy-
bridization studies performed on an additional case by 
Dr. Lawrence Weiss, City of Hope National Medical 
Center, Duarte, CA, demonstrated EBV nuclei acids 
FIG. 13. Autopsy liver tissue from a case with post-
transplant Iymphoproliferative disease: portal tract in-
filtrates hybridized strongly (arrows. inset) with a 358_ 
dCTP labelled probe consisting of the Bam H,-W frag-
ment of EBV DNA. 
within the lymphoid infIltrates in portal and sinusoidal 
locations (Fig. 13). 
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